Jeb Keiper, Nimbus Therapeutics CEO
PhIIb win puts Nimbus one step closer to challenging Bristol Myers in TYK2
Bristol Myers Squibb might be the first to clinch an FDA approval for a TYK2 inhibitor, but Nimbus Therapeutics is out to prove that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
